• KOLs
  • Breast Cancer
  • Solti Breast Cancer Research Group

Direct Impact

Concepts for which SOLTI Breast Cancer Research Group has direct influence:

breast cancer
endocrine therapy
hormone receptor
locally advanced
pam50 her2
oral vinorelbine
postmenopausal women

Prominent publications by SOLTI Breast Cancer Research Group

KOL-Index: 2 ONAWA is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of onapristone (ONA) on proliferation after 3 weeks of treatment in postmenopausal women with ER+/PgR+ and HER2-negative early breast cancer amenable to pre-operative endocrine therapy and surgery. Detailed Description The main hypothesis is that onapristone, an antiprogestin will induce a ...
Known for
Proliferative Arrest | Luminal Tumors | Neoadjuvant Endocrine | Natural Log
KOL-Index: 2 HER2-Predict is a multi-center, observational study using biological samples from patients treated with DS-8201a in the metastatic setting. Patients will provide a baseline FFPE tumor sample and additionally, blood sample for ctDNA determination will be collected.. HER2-Predict is a multi-center, observational study using biological samples from patients treated with DS-8201a in the ...
Known for
Ctdna Determination
KOL-Index: 2 ELIPSE is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of Elacestrant on proliferation after 4 weeks of treatment in postmenopausal women with Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-negative) early breast cancer (BC) amenable to surgery. Detailed Description The main hypothesis is that ...
KOL-Index: 2 SOLTI 1903 HOPE is a national, real world clinical practice study conducted in patients diagnosed with metastatic breast cancer who are receiving, have just received or will receive treatment for its advanced disease. Patients will lead their inclusion, participation and follow-up in the study through a digital tool, but they are encouraged to include their physician's in this study. Tissue ...
Known for
Detailed Eligible | Empowerment Program | Foundationone Cdx | Molecular Reports
KOL-Index: 2 This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line treatment for metastatic disease with a ...
Known for
Safety Activity
KOL-Index: 2 Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).The aim of PAMELA is to test the hypothesis that PAM50 HER2-enriched (HER2-E) subtype better predicts response to neoadjuvant dual anti-HER2 blockade, with or without endocrine therapy, compared to traditional clinical HER2 ...
Known for
Multicentric Translational | Untreated Primary | Enriched Her2 | Therapy Eligible
KOL-Index: 2 PROMETEO is a window opportunity, single arm, exploratory study to evaluate the effect of T- VEC combined with Atezolizumab in women with operable early breast cancer who present residual disease after Neoadjuvant Chemotherapy (NAC). Other eligibility criteria include TNBC or LumB like primary tumor sized at least 1.5 cm, ECOG PS 0-1 and evaluable diagnostic tumor sample. Detailed ...
Known for
Window Opportunity | Assess Rate | Surgery Neoadjuvant | Chemotherapy Include
KOL-Index: 2 Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer. Detailed Description The primary objective of this trial is to assess the efficacy of the combination of at least 5 ...
Known for
Adjuvant Systemic | Duration Palbociclib | Elderly Early | Combination Year
KOL-Index: 2 This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks.. This is a randomized, ...
KOL-Index: 2 The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer. Detailed Description Subjects will be randomized into one of two treatment arms ...
Known for
Therapeutic Resistance | Pik3ca Mutant

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172